蓝帆医疗 Medical announced on the evening of October 20 that the company's Biofreedom™ Ultra cobalt-chromium alloy stent has obtained the CE certificate and has the EU market access conditions and can be sold in the EU and related overseas markets. BioFreedom™Ultra can significantly inhibit the proliferation of vascular smooth muscle cells and effectively reduce the restenosis rate after percutaneous coronary intervention (PCI).
Menu